Angel Biotech acquires collagen plant in UK
ABH’s wholly owned subsidiary, Angel Biomedical Ltd (ABL) will take ownership of the manufacturing plant. The 6,500ft² facility comprises one large Grade C clean room, two smaller grade
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).